Consulting
Process Development
Analytical Services
Facility Design & Process EngineeringeXmoor Pharma is a full-service Cell & Gene Therapy CDMO with a difference. Backed by over 20 years of consultancy experience, we’ve helped more than 170 organisations accelerate therapies from discovery to delivery.
EXMOOR PHARMA
About Us
About eXmoor Pharma
Your Trusted Partner in Cell & Gene Therapy
For over two decades, eXmoor Pharma has been at the forefront of cell and gene therapy, guiding innovations from early development through to full-scale GMP manufacturing.
Our unique integration of consultancy and CDMO services ensures that every therapy we support is designed with commercial viability from the outset. With a global clientele exceeding 170 partners and a 70% repeat business rate, our commitment to excellence and long-term collaboration is evident.
Our state-of-the-art, purpose-built cell and gene therapy (CGT) facility offers comprehensive solutions across viral vectors, autologous and allogeneic cell therapies, and RNA technologies, solidifying our role as a true end-to-end partner in the advanced therapies landscape.
Our Story
2004
eXmoor was founded by Angela Osborne and four colleagues, including Gavin Sutton and Tim Nicholls, who continue to play key roles in the business today. Gavin leads our capital projects group, while Tim supports selected strategic initiatives. From the outset, the business specialised in cell therapy and biopharmaceutical manufacturing consultancy, with core expertise in facility design and process engineering.
2007
As the potential of cell and gene therapies (CGT) became clear, we broadened our focus to support biotech companies with CMC strategy, facility planning, and process optimisation.
2010
The first facility designed by eXmoor received MHRA licensure marking a major milestone in our journey from consultancy to delivering licensed, GMP-ready facilities.
2011
Our first product was released by an eXmoor Qualified Person (QP). Today, we employ multiple full-time QPs who not only provide product release on behalf of clients, but also contribute valuable GMP compliance insight across all stages of a project.
2017
After over a decade of consultancy success, we expanded into lab-based capabilities with the opening of our Process Development labs at Future Space in Bristol. This enabled us to offer practical process development, scale-up, analytical support, and pre-clinical material generation. Our first PD projects were AAV gene therapy programmes, supporting Meira GTx with tech transfer, upstream/downstream optimisation, and analytical development.
2019
We supported our first lentivirus project, scaling up to 10L suspension bioreactors and evaluating culture conditions for a US-based biotech company.
2021
Our first cell therapy project was completed, focused on Mesenchymal Stem Cells (MSCs).
2022
We completed our 500th client project, highlighting the scale and depth of our contributions across the CGT development lifecycle.
2023
We raised $35 million in Series A funding and opened the eXmoor Cell and Gene Therapy Centre—a 65,000ft² (6,000m²) GMP manufacturing facility in Bristol, UK. Designed and built by our own consultancy team, the Centre supports viral vector, cell therapy (autologous and allogeneic), and RNA manufacturing. It includes fill-finish, QC labs, and GMP-compliant storage.
2024
Our team grew to 85 staff and we received MIA(IMP) authorisation from the MHRA—an important regulatory milestone in expanding our GMP offering.
2025
Today, we combine 20 years of CGT experience with a commitment to accelerating life-changing therapies. More than manufacturing, we help innovators overcome regulatory and commercial hurdles to bring therapies to patients faster, and more sustainably.
Our Services
Integrated Consultancy & CDMO Services
Unlike traditional CDMOs, our embedded consultancy provides strategic guidance at every stage, from CMC strategy to facility design, ensuring seamless scalability and regulatory compliance.
Comprehensive Process Development
Our expertise encompasses process and analytical development for viral vectors, autologous and allogeneic cell therapies, and RNA technologies, facilitating efficient translation from research to clinical application.
State-of-the-Art GMP Manufacturing
Our 65,000 ft² (6,000m²) GMP facility in Bristol is equipped with Grade C cleanrooms, dedicated QC labs, and fill-finish suites, supporting both clinical and commercial manufacturing needs.
Tailored Facility Design & Engineering
With experience in designing over 45 CGT manufacturing facilities, we offer bespoke solutions that align with your commercial objectives, whether you require a custom-built facility or a fully managed site.
Client-Centric Approach
Our consultants integrate seamlessly into your team, offering flexible, impartial, and industry-leading guidance. We prioritize your intellectual property rights, ensuring you maintain full control over your innovations.
Our Team
We think our people are our greatest asset. With a team of over 80 experts spanning process development, GMP manufacturing, facility design, and CMC consulting, we bring unparalleled knowledge and experience to every project.
Our Approach
Our integrated approach to cell and gene therapy development combines scientific expertise with commercial insight, ensuring therapies reach patients faster. Guided by our mission and vision, we simplify complexity, de-risk development, and support every stage—from CMC strategy to GMP manufacturing.
Capability
eXmoor is backed by over 20 years experience helping 170+ organisations on their manufacturing journey.
Trust
We work as part of your team, developing lasting relationships based on trust, transparency and openness.
Collaboration
We work side-by-side with you to complement, enhance and build your capabilities.
Our Careers
Explore a career where science meets strategy.
We’re building a team of passionate people committed to shaping the future of cell and gene therapy.
Whether your expertise is in consultancy, process development, or GMP manufacturing, we offer the chance to work on impactful projects in a supportive, collaborative environment.
Frequently Asked Questions
Find answers to common questions about our capabilities, facility, services, and how we support your cell and gene therapy journey.
-
What is our scale of operation?
-
We operate from a purpose-built 65,000ft² (6,000m²) GMP facility in Bristol, designed to support cell and gene therapy developers from early-stage clinical programmes through to commercial manufacture. Our facility includes fully qualified Grade C cleanrooms, integrated fill-finish capability, QC labs, GMP warehousing, and 12,000ft² of expansion space for additional clinical, pivotal, or commercial manufacturing capacity.
-
What clinical phases can we support?
-
We support all clinical phases, from early development through to late-stage and commercial readiness. Whether you’re preparing for a first-in-human study or scaling up for Phase 3 clinical trials, we offer GMP manufacturing and regulatory expertise to help you progress with confidence.
-
Can we support commercial manufacturing?
-
Yes. Our GMP facility has been designed with commercial readiness in mind, including dedicated expansion space for large-scale vector, RNA, or cell therapy production. Our systems, quality oversight, and digital batch records meet the demands of global regulatory agencies, and our team brings experience from leading commercial manufacturing programmes.
-
What technology areas can we support?
-
We provide integrated services across:
- Autologous and allogeneic cell therapies (e.g. T cells, iPSCs, MSCs)
- Viral vectors (e.g. AAV, lentivirus, including scalable suspension processes)
- RNA technologies (e.g. mRNA, saRNA, cRNA with LNP encapsulation) We support process development, tech transfer, GMP manufacturing, and fill finish for these modalities within a single site.
-
Where is our facility located?
-
Our GMP facility is based in north Bristol, with excellent transport links for CGT supply chains. We’re close to the M4/M5 junction for road access, minutes from Bristol Parkway station with direct high-speed trains to London, and within easy reach of Bristol Airport and London airports. The site is accessible by lorry and includes ample parking for visitors, deliveries, and collections.
-
Can we support fill finish?
-
Yes. We offer GMP-compliant fill finish services for viral vectors, allogeneic cell therapies, and other small-batch biologics. Our fill finish suite includes a Grade C cleanroom and Grade A isolator, suitable for clinical-stage vial or bag filling. We provide this as a standalone service or integrated within a broader manufacturing programme, with full GMP oversight and documentation.
-
What is our position on online reviews?
-
We believe open and honest feedback is vital for transparency and improvement. While we welcome constructive input, we don’t support reviews that are deliberately misleading or intended to provoke. This kind of behaviour can distract from our mission to support life-changing therapies. For accurate information about our work or values, we encourage direct contact with our team.
-
What are social media auditors and how have they affected us?
-
Social media auditors are individuals who use platforms such as YouTube and Google Reviews to target organisations—often triggering coordinated campaigns involving false claims or misleading reviews. We were targeted by such a campaign in April 2024.
The interaction with the social media auditor did not reflect our core values, but it has resulted in a sustained effort by their followers to post false and defamatory content. In response, we’ve taken proactive steps to protect our people and uphold our standards. This includes additional training across the organisation to ensure our team is equipped to manage similar challenges professionally and confidently.
-
Why were we targeted, and why is this concerning?
-
It’s unclear why we were selected for a social media audit. As a company dedicated to developing life-changing cell and gene therapies for patients with limited treatment options, our work is both time-sensitive and highly specialised. Disruptions to our day-to-day operations, particularly in our laboratories, can directly delay the progress of vital new treatments.
We’re sharing this to remain transparent with our clients, employees, and partners, and to raise awareness of the broader harm such campaigns can cause, not just to us, but to the patient communities we serve.
We remain focused on our mission, supporting clients and collaborators while upholding the high standards of professionalism, transparency, and integrity that define who we are.
If you have any questions about this matter, please contact us at [email protected]
Let’s Accelerate Your Therapy Together
Choosing eXmoor Pharma means partnering with a team dedicated to accelerating your therapy’s journey from concept to patient, with a steadfast commitment to quality, innovation, and collaboration.